Cash, Cash Equivalents, and Marketable Securities
Eli Lilly Cash, Cash Equivalents, and Marketable Securities decreased by 55.3% to $177.20M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 51.8%, from $367.60M to $177.20M. Over 4 years (FY 2020 to FY 2024), Cash, Cash Equivalents, and Marketable Securities shows an upward trend with a 156.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher levels indicate strong liquidity and financial health, while lower levels may signal a need for external financing.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
Peer comparison
A standard liquidity metric reported by virtually all public companies on the balance sheet.
cash_equivalents_marketable_securities_totalHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $164.80M | $208.10M | $290.20M | $440.60M | $489.20M | $578.80M | $568.70M | $512.40M | $570.60M | $559.60M | $452.00M | $477.90M | $508.40M | $367.60M | $491.20M | $435.90M | $396.80M | $177.20M |
| QoQ Change | — | +26.3% | +39.5% | +51.8% | +11.0% | +18.3% | -1.7% | -9.9% | +11.4% | -1.9% | -19.2% | +5.7% | +6.4% | -27.7% | +33.6% | -11.3% | -9.0% | -55.3% |
| YoY Change | — | — | — | — | +196.8% | +178.1% | +96.0% | +16.3% | +16.6% | -3.3% | -20.5% | -6.7% | -10.9% | -34.3% | +8.7% | -8.8% | -22.0% | -51.8% |
Cash, Cash Equivalents, and Marketable Securities at Other Companies
Frequently Asked Questions
- What is Eli Lilly's cash, cash equivalents, and marketable securities?
- Eli Lilly (LLY) reported cash, cash equivalents, and marketable securities of $177.20M in Q3 2025.
- How has Eli Lilly's cash, cash equivalents, and marketable securities changed year-over-year?
- Eli Lilly's cash, cash equivalents, and marketable securities decreased by 51.8% year-over-year, from $367.60M to $177.20M.
- What is the long-term trend for Eli Lilly's cash, cash equivalents, and marketable securities?
- Over 4 years (2020 to 2024), Eli Lilly's cash, cash equivalents, and marketable securities has grown at a 156.2% compound annual growth rate (CAGR), from $11.40M to $491.20M.
- What does cash, cash equivalents, and marketable securities mean?
- The total value of the company's cash and highly liquid short-term investments.